Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2014-10-14 Regulatory Filings
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
FORM 8-A12G
Regulatory Filings Classification · 95% confidence The document is a Form 8-A12G filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It contains detailed descriptions of the company's securities, including common stock, preferred stock, warrants, and related provisions. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing to register securities. It does not contain financial statements or analysis but focuses on securities registration and related corporate governance provisions. Therefore, it fits best under Regulatory Filings (RNS). The document length (over 14,000 characters) and content confirm it is not a mere announcement but a substantive filing. Hence, the classification is RNS with high confidence.
2014-10-14 English
FORM 10-K
Annual Report FY 2014
2014-09-24 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting a change in the company's independent registered public accounting firm. It details the dismissal of the previous auditor and the appointment of a new auditor, including references to audit reports and letters to the SEC. This type of filing is a regulatory announcement about auditor changes and does not contain full financial statements or detailed audit reports themselves. It is not an Annual Report (10-K), Audit Report (AR), or Interim Report (IR), but rather a regulatory filing informing about a change in auditors. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content support this classification with high confidence.
2014-08-28 English
FORM 10-Q
Interim / Quarterly Report 9M 2014
2014-05-09 English
NANOANTIBIOTICS 10Q
Interim / Quarterly Report Q2 2014
2014-01-29 English
Interim / Quarterly Report 2013
Interim / Quarterly Report Q1 2013
2013-11-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.